Sildenafil Citrate

The study was undertaken with an aim to formulate effervescent tablet of sildenafil citrate and aspirin in combination to achieve the immediate release and fast action of sildenafil citrate on the body with shorter period of the time and to overcome the side effect of the sildenafil citrate by simultaneous release of aspirin. A 32 full factorial design was applied and it revealed that the bicarbonate source (X1) and concentration of binder (X2) significantly affected the independent variables effervescence time (Y1) and hardness (Y2). The optimized formulation having citric acid 23.65 %, tartric acid 6.30 %, sodium bicarbonate 37.85 %, potassium bicarbonate 12.61 % with binder concentration 2% and hardness adjusted to 3 kg/cm2. From among the 9 batches (D1 – D9) the D3 batch have desirable property, less effervescence time, enough hardness and immediate release profile.

Sildenafil Citrate (50mg) and Dapoxetine Hydrochloride (30mg) in combination used for the treatment of Premature ejaculation and Erectile dysfunction. Market survey and literature review revealed that there were so many methods available for single Sildenafil Citrate and DapoxetineHydrocloride and UV spectrophotometric method by absorbance correction method and simultaneous equation method (vierodt’s method) are available in 2013 . So it was thought of intrest to develop and validate simple, accurate, sensitive and rapid new UV spectrophotometric and RP-HPLC method for simultaneous estimation of Sildenafil Citrate and Dapoxetine Hydrochloride in Pharmaceutical dosage form. In RP-HPLC method, chromatographic separation was achieved on Hypersil ODS C18 (250mm x 4.6 mm id, 5m particle size) column using Methanol:Water buffer at pH 3 (pH of buffer was adjusted to 3.0 with dilute 0.5% ortho-phoshporic acid) (95:05 v/v) as mobile phase. Detection was carried out at 225 nm.